Lipoate is a covalently bound cofactor essential for five redox reactions in humans: in four 2-oxoacid
dehydrogenases and the
glycine cleavage system (GCS). Two
enzymes are from the energy metabolism, α-ketoglutarate
dehydrogenase and
pyruvate dehydrogenase; and three are from the
amino acid metabolism,
branched-chain ketoacid dehydrogenase, 2-oxoadipate
dehydrogenase, and the GCS. All these
enzymes consist of multiple subunits and share a similar architecture. Lipoate synthesis in mitochondria involves mitochondrial
fatty acid synthesis up to octanoyl-
acyl-carrier protein; and three lipoate-specific steps, including
octanoic acid transfer to
glycine cleavage H
protein by lipoyl(octanoyl)
transferase 2 (putative) (LIPT2), lipoate synthesis by
lipoic acid synthetase (LIAS), and lipoate transfer by lipoyltransferase 1 (LIPT1), which is necessary to lipoylate the E2 subunits of the 2-oxoacid
dehydrogenases. The reduced form
dihydrolipoate is reactivated by
dihydrolipoyl dehydrogenase (DLD). Mutations in LIAS have been identified that result in a variant form of
nonketotic hyperglycinemia with early-onset convulsions combined with a defect in mitochondrial energy metabolism with
encephalopathy and
cardiomyopathy. LIPT1 deficiency spares the GCS, and resulted in a combined 2-oxoacid
dehydrogenase deficiency and early death in one patient and in a less severely affected individual with a Leigh-like phenotype. As LIAS is an
iron-sulphur-cluster-dependent
enzyme, a number of recently identified defects in mitochondrial
iron-sulphur cluster synthesis, including NFU1, BOLA3, IBA57, GLRX5 presented with deficiency of LIAS and a LIAS-like phenotype. As in
DLD deficiency, a broader clinical spectrum can be anticipated for lipoate synthesis defects depending on which of the affected
enzymes is most rate limiting.